Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Trivano
Alles over “Farmaceutica”
Aandelen in “Farmaceutica”
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Aandeel
Datum
Koers
Evolutie
Even geduld...
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Nieuws over “Farmaceutica”
Toon enkel gratis nieuws
20/05 ·
Sanofi: Information concerning the total number of voting rights and shares - April 2024
· Persbericht
20/05 ·
Sanofi: Information concerning the total number of voting rights and shares - April 2024
· Persbericht
20/05 ·
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
· Persbericht
20/05 ·
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
· Persbericht
17/05 ·
Novo Nordisk A/S - share repurchase programme
· Persbericht
17/05 ·
Qilian International plans to adjust industrial investment
· Persbericht
17/05 ·
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®
· Persbericht
17/05 ·
BUXTON HELMSLEY RELEASES LETTER FROM CERTIFIED FRAUD EXAMINER ATTESTING TO DISCLOSURE FAILURES AND DEFICIENCIES BY ASSERTIO HOLDINGS BOARD OF DIRECTORS
· Persbericht
17/05 ·
AKRO Investors: Reminder - Important Deadline in Securities Fraud Class Action Lawsuit Akero Therapeutics, Inc.
· Persbericht
16/05 ·
CKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud Lawsuit
· Persbericht
16/05 ·
Voting Rights and Shares Capital of the Company
· Persbericht
16/05 ·
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
· Persbericht
16/05 ·
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
· Persbericht
16/05 ·
With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin
· Persbericht
16/05 ·
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
· Persbericht
16/05 ·
Bel-20 boekt licht herstel: grootste winst voor UCB
· Trends (€)
Lees in deze blog een dagelijks overzicht van de belangrijkste korte financieel-economische nieuwsberichten uit binnen- en buitenland. The post Bel-20 boekt licht herstel: grootste winst voor UCB appeared first on Trends.
15/05 ·
NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024
· Persbericht
15/05 ·
Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA
· Persbericht
15/05 ·
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
· Persbericht
15/05 ·
Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer
· Persbericht
15/05 ·
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
· Persbericht
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe